Gilead­'s newest ac­qui­si­tion: a liv­er dis­ease drug with $1B in peak sales po­ten­tial

Gilead’s ac­qui­si­tion of CymaBay Ther­a­peu­tics un­der­scores the com­pa­ny’s his­toric suc­cess in liv­er dis­eases and could bring in $1 bil­lion in peak an­nu­al sales.

Gilead an­nounced Mon­day that it will pay cash to buy CymaBay for $4.3 bil­lion, at $32.50 a share.

CymaBay is de­vel­op­ing se­ladel­par as a sec­ond-line treat­ment for pri­ma­ry bil­iary cholan­gi­tis, a rare, chron­ic and pro­gres­sive dis­ease. The drug, which showed off pos­i­tive Phase III re­sults in Sep­tem­ber, has a PDU­FA date in mid-Au­gust.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA